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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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Following up on news that it had halted dosing, Roche has
confirmed that its historic GENERATION HD1 clinical trial,
aimed at the genetic causes of Huntington’s disease, failed to
improve symptoms in study participants.
The disappointing trial outcome for the drug candidate tominersen
was revealed on April 27 by Scott Schobel, M.D., M.Sc., Roche’s
medical leader of GENERATION HD1, at the virtual 16th Annual
HD Therapeutics Conference, sponsored by CHDI Foundation,
Inc., the nonprofit virtual biotech focused solely on developing
HD treatments and a collaborator in the effort.
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“Nobody wanted this result,” Dr. Schobel said in his online talk,
the first scientific presentation describing why an independent
review committee had recommended, and Roche accepted, that
GENERATION HD1 be halted. “This is a setback, and it’s a
setback which is emotional. It’s a setback which we all feel,
because, after being able to lower the huntingtin protein for the
first time, there’s a lot of hope in that.”
An opportunity to learn
Dr. Schobel displayed a series of slides demonstrating
tominersen’s lack of effect on trial volunteers, who showed
“progressive decline,” reflected in key measures of cognition and
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control of bodily movements. Observations by physicians also
showed “increasing severity” of disease in the participants, Dr.
Schobel said.
Still, he said the researchers established a “new setpoint for the
field”: reducing the level of the mutant protein in the early-stage
tominersen clinical trial.
That achievement was a historic first, and many HD scientists still
believe that this strategy can lead to an improvement in symptoms.
However, it now remains for potential future trials to demonstrate
that huntingtin-lowering can actually help patients.
Roche is “compelled” to use the trial results “as an opportunity to
learn,” Dr. Schobel said. The company still has a “wealth of data”
to analyze regarding tominersen and its implications for the
huntingtin-lowering approach. The firm will share results with the
HD community.
The Huntington's Disease Society of America will hold a webinar
at noon Eastern time on April 29 with an update for the
community on the Roche results. (Click here to register.)

Dr. Scott Schobel of Roche displays slide demonstrating decline in
volunteers' condition in the GENERATION HD1 clinical trial at the 16th
Annual HD Therapeutics Conference (screenshot by Gene Veritas, aka
Kenneth P. Serbin)

Drug candidate’s target chosen
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On this first day of the three-day conference, Irina Antonijevic,
M.D., Ph.D., the chief medical officer at Triplet Therapeutics, Inc.,
revealed key details of the firm’s drug program to develop a
genetic strategy that contrasts sharply with the idea of lowering the
huntingtin protein. The firm also issued a press release.
Dr. Antonijevic focused on Triplet’s efforts to slow or stop a key
driver of HD, somatic expansion, the mutant huntingtin gene’s
tendency for continued expansion with age.
Triplet’s research exploits continuing breakthroughs in HD
genetics, also the topic of this year’s Therapeutics Conference.
Those advances have revealed that so-called modifier genes linked
to the speeding or slowing of somatic expansion can hasten or
delay the age of HD onset by just a few years or by as many as 40.
Triplet scientists and others believe that the longer that expansion,
the more toxic the gene and its product, the huntingtin protein,
become.
Building on these developments, in 2020 Triplet announced its
drug candidate TTX-3360, aimed at slowing or stopping somatic
expansion.
In her conference presentation, Dr. Antonijevic announced that the
specific biochemical target of TTX-3360 is the modifier gene
MSH3, involved in the maintenance and repair of DNA.
In studies of mice, Triplet has demonstrated safe and effective
lowering of MSH3 using TTX-3360. Additional safety studies
were done in nonhuman primates.
Injection directly into the brain
Like the Roche drug, TTX-3360 is an antisense oligonucleotide
(ASO), a synthetic modified single strand of DNA. Both the earlystage trial of tominersen and GENERATION HD1 delivered ASOs
via spinal tap.
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However, Dr. Antonijevic announced that TTX-3360 will be
introduced into the brain using an intracerebroventricular (ICV)
injection. The ICV device is a small reservoir implanted at the top
of the head with a catheter going into the brain. ICVs have been
used in medical treatments since the 1960s, including injection of
anti-cancer drugs.
Dr. Antonijevic explained that, in contrast with the spinal tap –
whereby an ASO had to travel along the spine before entering the
brain – the ICV will permit Triplet to get its drug deeper into the
brain, including areas severely affected by HD.
With spinal taps, patients can experience pain and inflammation
during dosing because of scarring that results from repeated
dosing, Dr. Antonijevic asserted. The ICV permits easy
withdrawal of cerebrospinal fluid (which bathes the brain) for
monitoring of drug safety and efficacy, she added.
The ICV also allows for rapid dosing – perhaps even at home –
whereas the spinal tap requires a visit to a doctor’s office, Dr.
Antonijevic pointed out.
(According to one scientific article, an ICV can remain in place for
life. However, long-term usage is not well understood. The device
should be monitored for leakage or failure. If necessary, the device
can be removed or replaced.)
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At the HD Therapeutics Conference, Dr. Irina Antonijevic of Triplet
Therapeutics discusses a slide comparing two methods of drug delivery:
spinal taps (intrathecal injections) and intracerebroventricular injection
(screenshot by Gene Veritas)

Triplet aims to file an investigational new drug application with
the U.S. Food and Drug administration (and/or a clinical trial
application in Europe or Canada) by year’s end for a Phase 1/2a
study of TTX-3360, which will address primarily the safety and
tolerability of the compound. Triplet will recruit presymptomatic
and early symptomatic individuals for the trial.
Triplet also announced a pledge of one percent of its equity to a
“patient support fund,” to be managed independently, to support
patients suffering from HD and other, similar disorders, known as
repeat expansion disorders. The fund will help patients and
families secure access to care and therapies.
(For background on the Triplet clinical trial program, click here.
Stay tuned to this blog here for further coverage of the
conference.)
(For additional coverage of the conference, click here).
Posted by Gene Veritas at 10:49 AM
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